Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free CHGCY Stock Alerts

Chugai Pharmaceutical (CHGCY) Stock Forecast & Price Target

Chugai Pharmaceutical logo
$26.41 -0.02 (-0.08%)
As of 03:59 PM Eastern
Compare

Chugai Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Strong Buy
Based on 2 Analyst Ratings
Sell
0
Hold
0
Buy
2

Based on 2 Wall Street analysts who have issued ratings for Chugai Pharmaceutical in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 2 analysts, 2 have given a strong buy rating for CHGCY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CHGCY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Chugai Pharmaceutical and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHGCY Analyst Ratings Over Time

TypeCurrent Forecast
5/5/25 to 5/5/26		1 Month Ago
4/5/25 to 4/5/26		3 Months Ago
2/4/25 to 2/4/26		1 Year Ago
5/5/24 to 5/5/25
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
 N/A
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
 N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingStrong BuyStrong BuyStrong BuyN/A

CHGCY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CHGCY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Chugai Pharmaceutical Stock vs. The Competition

TypeChugai PharmaceuticalMedical CompaniesS&P 500
Consensus Rating Score
4.00
2.30
2.52
Consensus RatingStrong BuyHoldModerate Buy
Predicted UpsideN/A887.21% Upside14.75% Upside
News Sentiment Rating
Positive News

See Recent CHGCY News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
2/25/2026
Smbc Nikko Sec. logo
Smbc Nikko Sec.
Not Rated
 UpgradeStrong-Buy
1/27/2026
UBS Group AG logo
UBS Group
4 of 5 stars
 UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 08:20 PM ET.


Should I Buy Chugai Pharmaceutical Stock? CHGCY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, May 3, 2026. Please send any questions or comments about these Chugai Pharmaceutical pros and cons to contact@marketbeat.com.

Chugai Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Chugai Pharmaceutical Co., Ltd.:

  • The current stock price is around $27.48, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • Chugai Pharmaceutical Co., Ltd. has received a "strong-buy" rating from multiple analysts, indicating strong confidence in the company's future performance.
  • The company reported a robust revenue of $2.25 billion for the latest quarter, showcasing its strong market position and operational efficiency.
  • With a return on equity of 22.00%, Chugai Pharmaceutical Co., Ltd. demonstrates effective management of shareholder equity, which is a positive indicator for potential investors.
  • The firm has a solid net margin of 34.47%, reflecting its ability to convert revenue into profit, which is crucial for long-term sustainability and growth.

Chugai Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Chugai Pharmaceutical Co., Ltd. for these reasons:

  • The stock has experienced volatility, with recent trading showing a gap down from previous closing prices, which may indicate market uncertainty.
  • Chugai Pharmaceutical Co., Ltd. operates in a highly competitive biopharmaceutical market, which can impact its market share and profitability.
  • The price-to-earnings (P/E) ratio is relatively high at around 31.97, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Market fluctuations and economic conditions can significantly affect the biopharmaceutical sector, posing risks to investment returns.
  • Analysts predict earnings per share of 0.74 for the current year, which may not meet investor expectations if growth does not accelerate.

CHGCY Forecast - Frequently Asked Questions

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last twelve months. There are currently 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" CHGCY shares.

According to analysts, Chugai Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Chugai Pharmaceutical's stock had 1 upgrade by analysts.

Chugai Pharmaceutical has been rated by research analysts at Smbc Nikko Sec. in the past 90 days.

Analysts like Chugai Pharmaceutical more than other "medical" companies. The consensus rating for Chugai Pharmaceutical is Strong Buy while the average consensus rating for "medical" companies is Hold. Learn more on how CHGCY compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Chugai Pharmaceutical Recommendations


This page (OTCMKTS:CHGCY) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel